Page 15 - Immune Sciences News Today

Biotech stocks managed to carve out modest gains for the week ending April 8, defying the broader market weakness. The defensive nature of th...

- Alpine to hold Investor Event on Tuesday, April 12th at 6:00pm ET - ... | March 30, 2022

Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Rating) – Stock analysts at Wedbush issued their Q1 2022 earnings per share (EPS) estimates for shares of Alpine Immune Sciences in a research note issued to investors on Monday, March 21st. Wedbush analyst R. Driscoll anticipates that the biotechnology company will earn ($0.27) per share for the […]

Zacks Investment Research cut shares of Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) from a hold rating to a sell rating in a report issued on Tuesday morning, Zacks.com reports. According to Zacks, “Alpine Immune Sciences Inc. operates as a specialty pharmaceutical company. It engages in the discovery and development of protein-based immunotherapies for the […]

Wall Street brokerages expect Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Rating) to post ($0.08) earnings per share (EPS) for the current quarter, Zacks reports. Two analysts have issued estimates for Alpine Immune Sciences’ earnings. Alpine Immune Sciences posted earnings per share of ($0.45) in the same quarter last year, which would indicate a positive […]

Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) posted its quarterly earnings results on Thursday. The biotechnology company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.23), MarketWatch Earnings reports. Alpine Immune Sciences had a negative return on equity of 58.85% and a negative net margin of 169.03%. Shares […]

<p><span>Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq Biotechnology Index (Nasdaq: NBI), which will become effective prior to market open on </span><span class="xn-chron">Monday, December 20, 2021</span><span>.</span></p>

NEW YORK, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq Biotechnology Index (Nasdaq: NBI), which will become effective prior

Alpine Immune Sciences will move a potential treatment for immune conditions into human testing and support its ongoing trials for cancer thanks to around $91…

Biogen isn't the only company whose shares should benefit from a breakthrough drug.